Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Laboratory Stakeholders Urge FDA To Ditch IVDMIA Guidance, Pursue Rule

This article was originally published in The Gray Sheet

Executive Summary

FDA should start over in its efforts to claim regulatory oversight of a new class of high-tech laboratory-developed tests through a guidance document and begin a formal rulemaking process, diagnostic industry stakeholders said at a Feb. 8 hearing
Advertisement

Related Content

Lab Stakeholders Still Oppose FDA’s Multivariate Assay Policy
FDA Takes Second Stab At Multivariate Diagnostic Oversight Guidelines
Kennedy And Obama Bills Target Home Brews, Genetic Tests
More dialogue on IVDMIAs
Emerging Diagnostic Firm Says It Got Mixed Messages From FDA
FDA Clears First-Of-A-Kind Breast Cancer Recurrence Test
FDA Clears First-Of-A-Kind Breast Cancer Recurrence Test
FDA Draft Guidances Assert Oversight Over Multiplex Tests
FDA Draft Guidances Assert Oversight Over Multiplex Tests
FDA, Agendia To Determine Scope Of MammaPrint Premarket Regulation
Advertisement
UsernamePublicRestriction

Register

MT024489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel